Search results
Results from the WOW.Com Content Network
The Gurugram-based digital health startup maintains an online medicine database with information on side effects and generic substitutes and provides home delivery services for pharmacy, FMCG, and lab tests. In June 2021, Tata Digital Ltd. acquired a 55% stake in 1mg to form Tata 1mg. [9] In 2023, Tata 1mg overtook PharmEasy as the market ...
February 2021 – BigBasket (68%) by Tata Digital; June 2021 – 1mg (55%) by Tata Digital; October 2021 – Air India, Air India Express and 50% stake in Air India SATS for ₹ 18,000 crore (US$2.1 billion). January 2022 – Nilachala Ispat Nigam Ltd, $1.5 billion; June 2023 – Kaleyra, Inc by Tata Communications for $100 million. [19]
Resmetirom, sold under the brand name Rezdiffra, is a medication used for the treatment of noncirrhotic nonalcoholic steatohepatitis. [1] It is a thyroid hormone receptor beta (NR1A2) agonist.
MedPlus Health Services is an Indian pharmacy retail chain, headquartered in Hyderabad. [3] MedPlus is the second largest pharmacy chain in India, operating over 4,230+ pharmacy stores across 600 cities, as of 2024.
PharmEasy competes with other e-pharmacy companies including Netmeds (which was acquired by Reliance Industries), 1mg (acquired by Tata Group), Apollo 24x7 and Amazon Pharmacy. [11] The Ken questioned the company's positioning as a unified healthtech player and referred to the company's story as "more confusing than convincing". [12]
Tata Translational Cancer Research Center (TTTRC) is a dedicated research facility embedded within Tata Medical Center. It was established in 2014, and moved to dedicated facilities in April 2018. The institute is housed within a dedicated academic space and is spread over 3 floors.
BGR-34 (Blood Glucose Regulator-34) [1] is an Ayurvedic-derived product that is sold in India as an over-the-counter pill for the management of type 2 diabetes.It was developed in 2015 by two government-owned laboratories and launched commercially in 2016.
The phase III trial for approval was published in 2000 as an industry-funded randomized, placebo-controlled trial (PCT). Its authors found 1 mg alosetron, taken orally twice daily for 12 weeks, was associated with a 12% (CI 4.7-19.2) improvement in relief from abdominal pain and discomfort associated with diarrhea-predominant patients. [4]